Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Shattuck Labs, Inc. - Common Stock (NQ: STTK ) 4.640 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Shattuck Labs, Inc. - Common Stock < Previous 1 2 3 Next > Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes July 01, 2024 From Shattuck Labs, Inc. Via GlobeNewswire Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid June 14, 2024 From Shattuck Labs, Inc. Via GlobeNewswire Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML) June 10, 2024 From Shattuck Labs, Inc. Via GlobeNewswire Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk June 06, 2024 From Shattuck Labs, Inc. Via GlobeNewswire Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the May 14, 2024 From Shattuck Labs, Inc. Via GlobeNewswire Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights May 02, 2024 From Shattuck Labs, Inc. Via GlobeNewswire Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024 April 09, 2024 From Shattuck Labs, Inc. Via GlobeNewswire Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference April 01, 2024 From Shattuck Labs, Inc. Via GlobeNewswire Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors March 04, 2024 From Shattuck Labs, Inc. Via GlobeNewswire Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights February 29, 2024 From Shattuck Labs, Inc. Via GlobeNewswire Shattuck Labs Announces Participation in Upcoming March Conferences February 26, 2024 From Shattuck Labs, Inc. Via GlobeNewswire Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases February 13, 2024 From Shattuck Labs, Inc. Via GlobeNewswire Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024 January 08, 2024 From Shattuck Labs, Inc. Via GlobeNewswire Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference January 04, 2024 From Shattuck Labs, Inc. Via GlobeNewswire Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants December 21, 2023 From Shattuck Labs, Inc. Via GlobeNewswire Shattuck Labs Inc. (NASDAQ: STTK) Leading the Way in Thursday Trading Based on Percentage Gain December 14, 2023 Via Investor Brand Network Shattuck Labs Inc. (NASDAQ: STTK) is One of Wednesday Morning’s Most Active Stocks December 13, 2023 Via Investor Brand Network Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) December 13, 2023 From Shattuck Labs, Inc. Via GlobeNewswire Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation December 05, 2023 From Shattuck Labs, Inc. Via GlobeNewswire Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference November 14, 2023 From Shattuck Labs, Inc. Via GlobeNewswire Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights November 09, 2023 From Shattuck Labs, Inc. Via GlobeNewswire Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023 November 06, 2023 From Shattuck Labs, Inc. Via GlobeNewswire Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 November 02, 2023 From Shattuck Labs, Inc. Via GlobeNewswire 10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis October 23, 2023 Via ACCESSWIRE Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights August 10, 2023 From Shattuck Labs, Inc. Via GlobeNewswire Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting May 25, 2023 From Shattuck Labs, Inc. Via GlobeNewswire Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights May 09, 2023 From Shattuck Labs, Inc. Via GlobeNewswire Shattuck Labs Announces Participation in Upcoming 22nd Annual Needham Virtual Healthcare Conference April 03, 2023 From Shattuck Labs, Inc. Via GlobeNewswire Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting March 16, 2023 From Shattuck Labs, Inc. Via GlobeNewswire Shattuck Labs Announces Participation in Upcoming March Conferences March 01, 2023 From Shattuck Labs, Inc. Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.